Announced Date: 2023-04-03 (April 3, 2023)
Asset Name: DB-1303(BNT323)，DB-1311(BNT324)
Licensor: Duality Biologics (Suzhou) (DualityBio, China)
Licensee (Buyer): BioNTech SE (DE)
.
Asset 1: DB-1303 (BNT323) (trastuzumab pamirtecan)
Asset Modality: ADC (antibody drug conjugate) , topoisomerase-1 inhibitor based
Asset Target: Human Epidermal Growth Factor Receptor 2 (HER2)
Potential Indication: HER2-expressing advanced solid tumors
Current Stage: Phase II, US
.
Asset 2: DB-1311 (BNT324)
Asset Modality: ADC (antibody drug conjugate) , topoisomerase-1 inhibitor based
Asset Target: B7-H3
Potential Indication: cancers
Current Stage:
.
Scope of Authority:
DualityBio has granted BioNTech exclusive license and collaboration agreements for two ADC assets to develop, manufacture and commercialize the two assets globally, excluding Mainland China, Hong Kong and Macau.
.
Deal Detail:
DualityBio eligible to receive:
Upfront payments totaling $170 million,
Development, regulatory and commercial milestone payments potentially totaling over $1.5 billion.
Single-digit to double-digit tiered royalties on potential future product sales.
.
Link:
